Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JTX-4014 alone versus JTX-4014 + vopratelimab in biomarker-selected metastatic NSCLC after prior platinum therapy
2019-004953-96Phase 2Completed
- Sponsor
- Jounce Therapeutics
- Start
- May 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of pimivalimab and vopratelimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Jounce Therapeutics. Primary endpoint: Mean percent change from baseline tumor size of all measurable existing and new lesions averaged over 9 and 18 weeks. Started May 2020; status: completed.
02
Drugs
pimivalimabvopratelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2019-004953-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004953-96.